Timolol eyedrops promising treatment for acute migraine: JAMA
Kerala, India: Timolol eye drops can be considered for the acute treatment of migraine, suggests a recent study in the journal JAMA Ophthalmology. According to the study, treatment with the eye drops reduced the main score within 20 minutes suggesting that topical β-blockers may be a promising therapeutic option for the treatment of acute migraine attacks.
However, the researchers stated that further research is warranted to determine if the observed improvements are sustained for a longer period of time and with larger groups.
Oral β-blockers that have been used for the prevention of migraine headaches are not effective for acute pain treatment. Small case series have suggested topically applied β-blockers to be beneficial for the management of acute migraine pain. Henceforth, Abraham Kurian, Chaithanya Eye Hospital and Research Institute, Kesavadasapuram, Trivandrum, Kerala, India, and colleagues evaluated the short-term safety and efficacy of topically applied timolol maleate ophthalmic solution, 0.5%, compared with topically applied placebo eyedrops in the treatment of acute migraine attacks.
The study included 50 migraine patient (average age 27.3 years; 84% were female) who were randomized to receive either timolol maleate ophthalmic solution, 0.5%, or placebo eyedrops (carboxymethyl cellulose, 0.5%) and were instructed to use 1 drop of the medication in each eye at the onset of their migraine.
The primary outcome of the study was pain score reduction by 4 points, or to zero, 20 minutes following the installation of the eyedrop.
Key findings of the study include:
- Of a total of 619 migraine attacks, 46% were treated with timolol, 44% were treated with the placebo, and 10% occurred during the washout period when no study medications were used.
- Seven patients (14%) withdrew after randomization.
- A total of 233 of the timolol-treated migraine attacks (82%) were associated with a reduction in pain score by 4 points, or to zero, at 20 minutes compared with 38 of the placebo-treated attacks (14%), with a difference of 68 percentage points.
- A generalized estimating equation analysis revealed that pain score reduction at 20 minutes was greater in the timolol group compared with the placebo group by a mean (SE) of 4.63 points.
"These findings support consideration of timolol eye drops in the management of acute migraine attacks, but a confirmation for longer follow-up with larger groups at multiple sites is warranted," concluded the authors.
"Short-term Efficacy and Safety of Topical β-Blockers (Timolol Maleate Ophthalmic Solution, 0.5%) in Acute Migraine: A Randomized Crossover Trial," is published in the journal JAMA Ophthalmology.
DOI: https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2771168
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.